Seroatlas · Human Serome Atlas

SPATA17

Spermatogenesis-associated protein 17

Also known as: CFAP305, FAP305, IQCH, MOT17, SPT17_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q96L03
Gene: SPATA17
Ensembl: ENSG00000162814
Chromosome: 1
Canonical length: 361 aa
Protein class: Predicted intracellular proteins
Subcellular location: Nucleoplasm,Nucleoli,Cytosol

OverviewNCBI Gene

Predicted to enable calmodulin binding activity. Predicted to be located in cytoplasm. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

361 residues, UniProt reviewed canonical sequence.

>Q96L03|SPATA17
     1  MATLARLQAR SSTVGNQYYF RNSVVDPFRK KENDAAVKIQ SWFRGCQVRA YIRHLNRIVT
    61  IIQKWWRSFL GRKQYQLTVQ VAYYTMMMNL YNAMAVRIQR RWRGYRVRKY LFNYYYLKEY
   121  LKVVSETNDA IRKALEEFAE MKEREEKKAN LEREEKKRDY QARKMHYLLS TKQIPGIYNS
   181  PFRKEPDPWE LQLQKAKPLT HRRPKVKQKD STSLTDWLAC TSARSFPRSE ILPPINRKQC
   241  QGPFRDITEV LEQRYRPLEP TLRVAEPIDE LKLAREELRR EEWLQNVNDN MFLPFSSYHK
   301  NEKYIPSMHL SSKYGPISYK EQFRSENPKK WICDKDFQTV LPSFELFSKY GKLYSKAGQI
   361  V

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against SPATA17 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.52
Highest tissue expression: 9.5 nTPM

Expression across tissuesHPA

Tissue

testis: 9.5 nTPM
fallopian tube: 3.8 nTPM
epididymis: 3.1 nTPM
choroid plexus: 2.6 nTPM
parathyroid gland: 2.4 nTPM
skeletal muscle: 1.9 nTPM

Single-cell type

late primary spermatocytes: 1,029 nCPM
ependymal cells: 1,025 nCPM
early spermatids: 820 nCPM
late spermatids: 746 nCPM
respiratory ciliated cells: 718 nCPM
choroid plexus epithelial cells: 585 nCPM

Immune cell

basophil: 0.3 nTPM
neutrophil: 0.2 nTPM
gdT-cell: 0.1 nTPM
MAIT T-cell: 0.1 nTPM
memory B-cell: 0.1 nTPM
naive B-cell: 0.1 nTPM

Brain region

choroid plexus: 7.6 nTPM
medulla oblongata: 6.4 nTPM
pons: 6.2 nTPM
midbrain: 5.9 nTPM
cerebellum: 4.9 nTPM
white matter: 4.9 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.81
gnomAD pLI: 0
gnomAD missense Z: -0.79
DepMap mean gene effect: 0.08
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Molecular functions

calmodulin binding

Cellular components

cytoplasm

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads SPATA17 as an antibody target. Whether an autoantibody or antibody against SPATA17 could matter depends on whether native SPATA17 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

SPATA17 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label SPATA17 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...